Hologic (HOLX) Tops Q3 EPS by 3c; Raises Outlook

Hologic (NASDAQ: HOLX) reported Q3 EPS of $0.51, $0.03 better than the analyst estimate of $0.48. Revenue for the quarter came in at $717.4 million versus the consensus estimate of $704.27 million.

"We posted very good results across the board in our fiscal third quarter," said Steve MacMillan, Hologic's Chairman, President and Chief Executive Officer. "Despite difficult comparisons in the prior year period, global sales grew in all four of our businesses, led by GYN Surgical. In addition, we continue to improve gross and operating margins, and our capital deployment efforts helped EPS increase significantly faster than revenue."

GUIDANCE:

Hologic sees Q4 2016 EPS of $0.49-$0.50, versus the consensus of $0.50. Hologic sees Q4 2016 revenue of $714-724 million, versus the consensus of $728.4 million.

Hologic sees FY2016 EPS of $1.93-$1.94, versus prior guidance of $1.89-$1.91 and the consensus of $1.91. Hologic sees FY2016 revenue of $2.81-2.83 billion, versus the consensus of $2.82 billion.

For earnings history and earnings-related data on Hologic (HOLX) click here.

You May Also Be Interested In

• Hologic recalls BioZorb markers after reported injuries - FDA
• Waste stocks ride AI and healthcare boom as CLH surges 27%
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM